An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease-Reference-Cited by-同舟云学术

An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease

Published:2019-09-06 Issue:10 Volume:34 Page:1633-1652
ISSN:0179-1958
Container-title:International Journal of Colorectal Disease
language:en
Short-container-title:Int J Colorectal Dis

Author:

Ebada Mahmoud Ahmed^ORCID,Elmatboly Abdelmagid M.,Ali Ahmed Said,Ibrahim Ahmed Mohamed,Fayed Notila,Faisal Ahmed Faisal,Alkanj Souad

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00384-019-03354-7.pdf

Reference56 articles.

1. Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J (2016) Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol 51:1062–1068. https://doi.org/10.3109/00365521.2016.1149883

2. Rutgeerts P, Assche GVAN, Vermeire S (2006) Review article : infliximab therapy for inflammatory bowel disease – seven years on:451–463. https://doi.org/10.1111/j.1365-2036.2006.02786.x

3. Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M (2017) Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months. Dig Dis Sci 62:1305–1312. https://doi.org/10.1007/s10620-017-4511-4

4. Jahnsen J, Detlie TE, Vatn S, Ricanek P (2015) Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 9:S45–S52. https://doi.org/10.1586/17474124.2015.1091308

5. Jung YS, Il PD, Kim YH et al (2015) Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 30:1705–1712. https://doi.org/10.1111/jgh.12997

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Diet-Induced Weight Loss on Inflammatory Status and Hyperandrogenism in Women with Polycystic Ovarian Syndrome (PCOS)—A Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2024-08-21

2. Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis;Journal of Crohn's and Colitis;2024-04-24

3. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study;Digestive and Liver Disease;2024-01

4. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis;Age and Ageing;2024-01-01

5. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses;Scandinavian Journal of Gastroenterology;2023-11-25